Curocell: Pre-revenue biotech with widening losses and a share price down 40.3% over one year

Thesis

The data shows a company still in a loss-making, pre-revenue phase. Operating losses have stayed in a range of ₩31.1B to ₩36.6B per year, and the trailing net loss of ₩54.1B is larger than any full-year loss shown. The share price has risen 9.2% over the past month but is down 1.7% over three months and 40.3% over one year, and it sits close to the 52-week low of ₩20,650 (high ₩66,000).

The data does not show product sales, guidance, or the pipeline, so the progress of the business cannot be judged from it. Ownership by foreign investors is small at 1.4%, and the short balance is 0.6%, so neither points to strong positioning. Several filings on 5%+ holdings and management matters appear in recent months, but their content is not given.

Business overview

Curocell was founded in December 2016 and listed on the KOSDAQ on 9 November 2023. It is classed in Biotech & Pharma and has 15,227,152 listed shares. The CEO is listed as 김건수. Revenue has been zero in every period in the data, so the numbers describe a development-stage company funded by capital and borrowings rather than sales. No recent news headlines are available in the data.

Financial analysis

These figures come from filed financial statements. Revenue was ₩0 in 2023, 2024, 2025 and over the trailing twelve months to H1 2026, so margins and growth cannot be calculated.

Operating loss was ₩31.1B in 2023, ₩36.6B in 2024, ₩36.3B in 2025 and ₩35.4B over the trailing period. Net loss was ₩29.6B in 2023, ₩38.2B in 2024, ₩46.3B in 2025 and ₩54.1B trailing. Net loss has therefore widened faster than operating loss.

Return on equity was -50.0% in 2023, -86.4% in 2024, -268.6% in 2025 and -106.1% trailing. Equity is thin, which makes the ratio swing widely.

At H1 2026, cash was ₩17.1B against borrowings of ₩58.7B. Liabilities to equity were 127.0%. Trailing free cash flow was -₩30.3B, so cash on hand covers roughly half a year at that pace, based on the figures shown.

Valuation

Price-to-earnings, price-to-sales and EV/EBITDA cannot be calculated because earnings and revenue are negative or zero. Price-to-book is 4.9, down from 9.2 at the end of 2023, 16.1 at the end of 2024 and 136.2 at the end of 2025. Enterprise value is about ₩394.0B. Dividend yield is 0.0%.

Peers show price-to-book of 8.1 for Samsung Biologics, 2.5 for Celltrion, 29.1 for Alteogen, 2.6 for Yuhan and 5.9 for SK biopharmaceuticals, but those companies are profitable with P/E of 15.0 to 81.0, so the comparison is limited. No model estimate per share is available because the valuation model could not be worked out. The closing price was ₩23,150.

Catalysts

• The half-year report filed on 14 August 2026 is the latest full set of figures and shows the cash and borrowing position.
• Filings on 16 June and 22 May 2026 about major management matters could matter, though their content is not in the data.
• A notice on the grant of stock purchase options was filed on 27 May 2026.
• Three 5%+ holding reports were filed between 28 May and 23 July 2026, indicating changes among large shareholders.
• Insider shareholding reports on 21 October and 9 September 2026 show continued insider activity.

Risks

• Zero revenue and trailing free cash flow of -₩30.3B mean the company depends on outside funding.
• Cash of ₩17.1B is small next to borrowings of ₩58.7B, which could lead to financing or dilution.
• Net loss widened from ₩29.6B in 2023 to ₩54.1B trailing, and ROE is -106.1%.
• The share price is down 40.3% over a year and near its 52-week low, showing weak sentiment.
• Over 20 days foreign investors were net sellers of about ₩1.1B while retail investors were net buyers of about the same amount, and valuation measures are mostly unavailable.

Closing view

The data describes a pre-revenue biotech with persistent losses, thin cash relative to borrowings, and a share price that has fallen sharply over the year. Price-to-book has compressed from very high levels, but it is hard to interpret with equity so low and no earnings. With no model estimate, no revenue and no news in the data, the evidence is incomplete, and the key open questions are funding and the progress of the business, neither of which the data answers.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

• Insider shareholding reportOct 21, 2026
• Insider shareholding reportSep 9, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• Insider shareholding reportJul 24, 2026
• 5%+ holding reportJul 23, 2026
• 5%+ holding reportJul 22, 2026
• Major management matter relevant to investorsJun 16, 2026
• Insider shareholding reportJun 2, 2026
• 5%+ holding reportMay 28, 2026
• Notice on Grant of Stock Purchase OptionsMay 27, 2026
• Major management matter relevant to investorsMay 22, 2026
• Insider shareholding reportMay 15, 2026
• Daily prices up to 2026-10-23
• Financial statements, trailing 12 months as of H1 2026

Report history

1. Oct 24, 2026InitiationStart of coverage (reader request)Curocell: Pre-revenue biotech with widening losses and a share price down 40.3% over one year